Childhood obesity (Print)

Cost-Effectiveness of Obesity Care and Treatments for Teenagers

Updated

Abstract

Phentermine-topiramate yielded an incremental cost-effectiveness ratio (ICER) of $112,141/QALY compared to lifestyle modification under perfect access conditions.

  • Semaglutide showed an ICER of $166,513/QALY when compared to phentermine-topiramate with perfect access.
  • Under imperfect access, cost-effectiveness declined by 11%, and the percentage of averted obesity cases dropped from 57% to 3% for semaglutide.
  • Health gains were notably lowest for adolescents insured by Medicaid and those identifying as Black or Hispanic.
  • ICERs were influenced by medication characteristics, including costs, effectiveness, and discontinuation rates.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free